Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Pacira BioSciences's EV/EBITDA was 14.9× on Nov 11, 2026, against 8.6× a year earlier. Over the last 5 years it ranged from 1.7× to 248.3×, with a median of 11.5×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 14.9× | +5.5 |
| 2025 | Dec 31, 2025 | 9.4× | −28.0 |
| 2024 | Dec 31, 2024 | 37.4× | +27.3 |
| 2023 | Dec 29, 2023 | 10.1× | +0.4 |
| 2022 | Dec 30, 2022 | 9.7× | −6.2 |
| 2021 | Dec 31, 2021 | 15.9× | −26.0 |
| 2020 | Dec 31, 2020 | 41.8× | +0.8 |
| 2019 | Dec 31, 2019 | 41.0× | −14.4 |
| 2018 | Dec 31, 2018 | 55.4× | −62.0 |
| 2016 | Oct 31, 2016 | 117.4× | +3.6 |
| 2015 | Dec 31, 2015 | 113.8× | – |
See a number that looks wrong?